Hospira nabs Indian API plant for $200M

Hospira ($HSP) has snapped up an API plant and R&D facility from India's Orchid Pharmaceuticals. The $200 million deal will secure supplies of active ingredients for certain antibiotics and will help it cut costs as well. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.